Companies Dominating the Somatostatin Analogs Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sun Pharmaceutical Industries Ltd
- Midatech Pharma PLC
- Ipsen Pharma, Chiasma Inc.
- Peptron, Inc
- CRINETICS PHARMACEUTICALS
- Dauntless Pharmaceuticals
- Camurus AB
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of somatostatin analogs is evaluated at USD 8.03 billion.
The somatostatin analogs market size was over USD 7.57 billion in 2024 and is poised to exceed USD 18.69 billion by 2037, witnessing over 7.2% CAGR during the forecast period i.e., between 2025-2037. Rising prevalence of Cushing syndrome and growing launch of advanced drug therapies for rare diseases will drive the market growth.
North America industry is anticipated to account for largest revenue share of 49% by 2037, due to availability of key players such as Pfizer Inc. and Novartis AG in the region.
The major players in the market are Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc., Peptron, Inc., CRINETICS PHARMACEUTICALS, Dauntless Pharmaceuticals, Camurus AB, Teva Pharmaceuticals Inc, and Pfizer Inc.
